PDF(Pubmed)
Abstract：
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) has become the leading cause of chronic liver disease. Liver biopsy, as the diagnostic gold standard, is invasive and has sampling bias, making it particularly important to search for sensitive and specific biomarkers for diagnosis. Cytokeratin 18 (CK18) M30 and M65 are products of liver cell apoptosis and necrosis, respectively, and liver-expressed antimicrobial peptide 2 (LEAP-2) is a related indicator of glucose and lipid metabolism. Correlation studies have found that all three indicators positively correlate with the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Through comparison of diagnostic values, it was found that CK18 M65 can better distinguish between healthy individuals and MAFLD; LEAP-2 can effectively distinguish MAFLD from other liver diseases, especially ALD.
摘要：
代谢功能障碍相关脂肪性肝病（MAFLD）已成为慢性肝病的主要原因。肝活检,作为诊断的黄金标准，是侵入性的，有抽样偏差，这使得寻找敏感和特异的诊断生物标志物尤为重要。细胞角蛋白18（CK18）M30和M65是肝细胞凋亡和坏死的产物，分别,肝表达抗菌肽2(LEAP-2)是糖脂代谢的相关指标。相关研究发现，所有三个指标都与肝酶丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）呈正相关。通过诊断价值的比较，研究发现，CK18M65可以更好地区分健康个体和MAFLD;LEAP-2可以有效区分MAFLD与其他肝脏疾病，尤其是ALD。
